Introduction
Cells can dynamically communicate with the extracellular environment via secretory molecules. The secreted molecules can act as para-or autocrine factors in cell signaling and gene expression [1, 2] . The two major pathways for secreting proteins across the plasma membrane in eukaryotes are the classical (endoplasmic reticulum (ER)/Golgi-dependent) and non-classical (endoplasmic reticulum (ER)/Golgi-independent or unconventional) pathways. Identification of the non-classical pathway was based on the observation that communication with neighboring cells via extracellular secretion of signaling proteins can occur even in absence of a signal peptide, an N-terminal extension sequence, or the ER membrane translocation machinery. Signaling molecules that are secreted via the non-classical pathway include: fibroblast growth factor-2 (FGF-2), an angiogenesis stimulant essential for tumor growth and metastasis [3] ; galectin-1, an inducer for tumor-mediated immune suppression [4] ; and cytokine interleukin-1β (IL-1 β) from activated macrophages, a mediator of the inflammatory response involved in cell proliferation, differentiation, and apoptosis [5] .
The apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1), a typical nuclear protein with a pleiotropic role in oxidative stress response, has also been found in the mitochondria of metabolically active and proliferative cells [6, 7] . Recent studies have indicated that APE1/Ref-1, which is localized in the cytoplasm, is susceptible to post-translational modification (PTM), such as nitrosylation or acetylation [8, 9] . Interestingly, APE1/Ref-1 protein secretion showed remarkable regulatory effects on inflammatory cytokine-stimulated cells both in vitro and in vivo [10] [11] [12] . Moreover, in different tumor cell types, the level of APE1/Ref-1 was abnormally high [13, 14] , suggesting its 2 of 14 possible use as a cancer biomarker. The different subcellular distribution of APE1/Ref-1 and the evidence of its extracellular secretion together suggest that its distribution and translocation are controlled not only by stimulatory agents like chemicals or hormones but also by plasma membrane transporters. Although APE1/Ref-1 has been demonstrated to accumulate along the plasma membrane in the presence of a deacetylase inhibitor, trichostatin A (TSA) [15] , the mechanism of its translocation across the plasma membrane remains unknown.
In this study, we hypothesized that APE1/Ref-1 is secreted by a membrane transporter since its plasma membrane translocation depends on PTM [16] [17] [18] , and appears to be controlled by extracellular factors whose identities are still under investigation. To identify the transporter pathway for APE1/Ref-1, we used pharmacological inhibitors that prevent the secretion of intracellular proteins by targeting specific transporters, such as the ABC transporter A1 (ABCA1). In the present study, we established the identity of the transport pathway for APE1/Ref-1 and our results will facilitate the analysis of the extracellular roles of this multifunctional protein. Figure 1A ,B. TSA concentrations used in the present study were within the range used previously to document the acetylation of intracellular proteins [9] , without affecting the viability of HEK293T cells ( Figure 1B Figure 1A ). Since TSA induced APE1/Ref-1 secretion, we examined the effects of secretory pathway inhibitors on its secretion. Pre-exposure of TSA-treated HEK293T cells to brefeldin A (BFA), an inhibitor of the ER-to-Golgi classical transport pathway, had no effect on Ac-APE1/Ref-1 secretion ( Figure 1C ), whereas TNF-α secretion, which depends on the classical secretory pathway, was abrogated ( Figure 1D ). These results together indicated that TSA treatment increased APE1/Ref-1 secretion via non-classical transport pathways. Columns, mean (n = 15-20); dot plot, SE. *** p < 0.001 indicates a significantly different result from control cells according to an unpaired t-test. (B) Effects of TSA on the viability of HEK293T cells were determined using a bioluminescent assay Columns, mean (n = 6); bars, non-significantly different from control cells according to an unpaired t-test. (C) HEK293T cells were pretreated with brefeldin A (BFA), a classical secretory pathway inhibitor, followed by 1 µM TSA treatment for 3 h. The total amount of secreted Ac-APE1/Ref-1 in cell-free supernatant was analyzed by ELISA. (D) The total amount of secreted TNF-α from LPS-stimulated RAW 264.7 cells before exposure to BFA at the indicated concentration. Column, mean (n = 5); bars, SE. * ,# , p < 0.05 indicates a significantly different result compared with control or between groups by one-way ANOVA followed by Bonferroni's multiple comparison test.
Results

Non-Classical
Extracellular Secretion of APE1/Ref-1 Was Decreased by ABC Transporter Inhibitors
ABC transporters were used to transport a variety of substrates across cell membrane including ions, lipid, amino acids, even proteins [19] . As established APE1/Ref-1 secretion is mediated with non-classical transport pathway, we focused on the effect of an ABC transporter on APE1/Ref-1 secretion in TSA-treated HEK293T cells. As shown in Figure 2A , the secretion of APE1/Ref-1 from TSA-treated HEK293T cells was affected when the cells were pre-exposed to probenecid, a broadspectrum inhibitor of ABC transporters. Probenecid-pretreated cells stimulated with TSA (0.39 ± 0.02 ng/2 × 10 5 cells) showed significantly inhibited APE1/Ref-1 secretion compared to TSA-onlystimulated cells (0.85 ± 0.06 ng/2 × 10 5 cells). As shown in Figure 2C , interestingly, APE1/Ref-1 secretion was also significantly reduced by more than 50% after pretreatment with glyburide [20, 21] , a selective inhibitor of ABC transporters such as ABCA1, ABCB1, ABCB11, ABCC1, ABCC2, ABCC3, ABCC8, and ABCC9 [22] [23] [24] [25] [26] [27] . The exposure of two inhibitors did not affect cell viability, as shown in Figure 2C , interestingly, APE1/Ref-1 secretion was also significantly reduced by more than 50% after pretreatment with glyburide [20, 21] , a selective inhibitor of ABC transporters such as ABCA1, ABCB1, ABCB11, ABCC1, ABCC2, ABCC3, ABCC8, and ABCC9 [22] [23] [24] [25] [26] [27] . The exposure of two inhibitors did not affect cell viability, as shown in Figure 2B 
ABCA1 Transporter Was Involved in the Secretion of APE1/Ref-1
To identify the ABC transporter responsible for the secretion of APE1/Ref-1, we determined the presence of ABC transporters in HEK293T cells. Expression of ABCA1, ABCB1, ABCC1, ABCC2, and ABCC8 transporters were detected in the HEK293T cells ( Figure 3A ). We proceeded to determine the functional significance of each ABC transporter in TSA-treated HEK293T cells using siRNA. Columns, mean (n = 3); bars, SE. # p < 0.05 indicated a significantly different result from TSA treated cells or between groups by two-way ANOVA followed by Bonferroni's multiple comparison test.
Acetylation of APE1/Ref-1 Was Required for Binding to ABCA1 Transporter
We next tested whether the acetylation of APE1/Ref-1 was specifically required for both the binding to ABCA1 transporter and subsequent translocation of the protein to the exterior of the cell. We examined the role of acetylation using two different, yet complementary approaches. We first performed a co-immunoprecipitation experiment to confirm that APE1/Ref-1 was directly associated with the ABCA1 transporter. Acetylation of intracellular proteins by TSA treatment enabled the binding of exogenously overexpressed APE1/Ref-1-FLAG to the ABCA1 transporter, as Figure 5D ). Figure 4C ). This result was also supported by comparing the efficient co-immunoprecipitation of wild-type APE1/Ref-1-FLAG with ABCA1. Figure 5C , TSA-induced APE1/Ref-1 enrichment was detected in the plasma membrane fraction and was confirmed using an anti-N-cadherin antibody. TSA-treated cells had an approximately 3-fold higher content of plasma membrane-located APE1/Ref-1 compared to the control cells ( Figure 5D ). Column mean (n = 3); bars, SE.*, p < 0.05 indicates a significantly different result compared with control or between groups by one-way ANOVA followed by Bonferroni's multiple comparison test.
APE1/Ref
-1 with ABCA1 was visualized by numerous red spots, indicating a proximal interaction between APE1/Ref-1 and ABCA1 transporter (< 40 nm). In contrast, TSA-treated HEK293T cells, expressing mutant APE1/Ref-1(K6/7R)-FLAG, showed only weak background signals. These results demonstrated that APE1/Ref-1 directly interacted with ABCA1 transporter as a prerequisite for its secretion in TSA-treated HEK293T cells (
4-fold higher quantities of Ac-APE1/Ref-1, compared with control cells (Figure 5B
). Finally, we proceeded to examine the trafficking of APE1/Ref-1 to the plasma membrane in TSA-treated HEK293T cells. As shown in
Discussion
Previous studies have demonstrated that APE1/Ref-1, a typical nuclear protein, is also present in the extracellular milieu of cells associated with chronic diseases [11, 13, [28] [29] [30] . Identification of its secretory pathway would clarify whether the detection of APE1/Ref-1 in extracellular samples is an experimental artifact or is the result of a controlled cellular response to certain stimulators. The major finding of this study was that APE1/Ref-1 is secreted from cells stimulated for protein acetylation via a non-classical secretory pathway that involves ABCA1 transporter. Since probenecid and glyburide treatment caused significant inhibition of Ac-APE1/Ref-1 secretion, suggesting the involvement of a non-classical secretory pathway with ABCA1 transporter, we focused on ABCA1 as a transporter candidate based on the following experimental data: (i) dominant expression in HEK293T cells, (ii) transporter-specific pharmacological inhibition, and (iii) knock-down using specific ABCA1 siRNA. Some studies have suggested that protein translocation mediated by ABC transporters requires protein unfolding, which is a general prerequisite for protein translocation complexes across membranes [31, 32] . However, some non-classical secretion of FGF-2 and Gal-1 does not require protein unfolding [33, 34] . ABCA1 is a membrane protein, and affects secretion of various proteins such as the macrophage migration inhibitory factor (MIF) and interleukin-1beta (IL-1β) [20, 26] . Moreover, the direct involvement of ABC transporters has been demonstrated for lipid transport [35] , such as vesicle export [36] . In a previous study, TSA-mediated acetylation was shown to cause PTM of APE1/Ref-1 (30 Lys residues in APE1/Ref-1), attaching an acetyl group to the ε-amino group of lysine residues [37] . Acetylation reduces the net charge and increases the hydrophobicity of APE1/Ref-1 [38] . Intracellular imbalance can influence the interplay between survival pathways and cell death, causing cell cycle arrest, re-differentiation, or metabolic reprogramming. Intracellular imbalance is increased under inflammatory conditions associated with lung disease [39] , vascular disease [40] , hemorrhage, and sepsis [41] , acetylation combined with coordinated expression of multiple inflammatory genes. Considering these reports, TSA-mediated acetylation in this study is an important observation for explaining the export of intracellular APE1/Ref-1. Recently, we have shown that APE1/Ref-1 is extracellularly secreted in an LPS-stimulated endotoxemic rat model [11] . The extracellular APE1/Ref-1 plays the role in disulfide bond exchange within the TNF receptor, causing inhibition of vascular inflammatory signals [10] . Stimulation of the APE1/Ref-1 secretion is triggered by its acetylation, as shown by diminished secretion level of the mutant APE1/Ref-1(K6/7R) due to mutated lysine, thus supporting the critical role played by lysine acetylation in various cardiovascular diseases [28] . Although deacetylation of Ac-APE1/Ref-1 followed time-dependent kinetics, eventually reaching an optimum, the recovery mechanism of Ac-APE1/Ref-1 to its non-acetylated form with respect to its reductase activity requires further studies. These observations raised the question of whether secreted APE1/Ref-1 can be influenced in an extracellular inflammatory environment. These results also suggested that extracellular APE1/Ref-1 with redox activity could be considered for further clinical investigation to determine its possible therapeutic efficacy against chronic inflammation, owing to its potential role in the early prevention of inflammatory signals in vivo.
In summary, our current study indicated that the extracellular secretion of APE1/Ref-1 depends on acetylation, a common PTM in eukaryotic cells. Ac-APE1/Ref-1 is intracellularly targeted to the plasma membrane and translocated by ABCA1 membrane transporter for secretion into the extracellular milieu.
Materials and Methods
Materials
TSA, brefeldin A (BFA), glyburide, probenecid, suberoylanilide hydroxamic acid (SAHA), valproic acid, butyrate and lipopolysaccharide (LPS) were purchased from Sigma Aldrich (St. Louis, MO, USA). Lipofectamine®RNAiMAX, Opti-MEM™ media, and Dynabeads ® Magnetic beads were purchased from Thermo Fisher Scientific (San Jose, CA, USA). ABCA1 small interfering RNA (siRNA), control siRNA, and primers were purchased from Bioneer (Daejeon, Korea). Complementary DNA synthesis kit and PCR PreMix kit were purchased from Intron biotechnology Inc. (Seongnam, Gyeonggi-do, Korea). Mouse tumor necrosis factor (TNF)-α ELISA kit was purchased from R&D system (Minneapolis, MN, USA). Anti-N-cadherin antibody was purchased from Abcam (cat.no. ab18203, Cambridge, MA, USA); anti-β-actin antibody was purchased from Sigma Aldrich (cat.no. A5316, St. Louis, MO, USA); Monoclonal anti-ABCA1 antibody (cat.no. sc-58219, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and polyclonal antibody (cat.no. PA1-16789, Invitrogen, Waltham, MA, USA) were used. Monoclonal (cat.no. NB100-116, Novus Biologicals, Littleton, CO, USA) and polyclonal antibodies against APE1/Ref-1 (cat.no. MR-PAAPE, MediRedox, Daejeon, Korea) were used.
Cell culture and treatment
Human embryonic kidney 293T (HEK293T) cells and Raw 264.7 cells were cultured in Dulbecco's modified Eagle's medium (Welgen, Korea) with 10% fetal bovine serum and 1% antibiotics. Each cell line was incubated under humid conditions at 37 • C and 5% CO 2 . Cells were seeded into well plates and incubated for 24 hours, followed by replacement of the culture medium with Opti-MEM™. The cells were treated with the inhibitor for 2 h, followed by TSA treatment for 1 h, as indicated. Cell viability was analyzed using the RealTime-Glo TM MT luminescent kit (Promega, Madison, WI, USA) in an opaque-walled assay plate, according to the manufacturer's instructions and as reported previously [42] .
Enzyme-linked immunosorbent assay (ELISA)
The amount of APE1/Ref-1 in each sample was determined by ELISA analysis (MediRedox, Daejeon, Korea) [43] . HEK293T cells were grown to confluence on a 12-well plate (2 × 10 5 cells/well) and then changed with Opti-MEM™ medium. Then, the cells were treated with 1 µM TSA in 0.5 mL Opti-MEM™/well, and to obtain cell-free supernatant, the medium was collected by centrifugation at 1200 rpm for 3 min. Supernatant without cell debris was carefully recovered and re-centrifuged at 3000 rpm for 3 min. The final supernatant was used for detection of secretory APE1/Ref-1. Each sample was assayed in duplicate.
For the measurement of TNF-α concentrations in the cell culture medium, the supernatant was obtained from LPS (300 ng/ml)-treated Raw 264.7 cells. The level of TNF-α was determined using a mouse TNF-α ELISA kit (BD Pharmingen, San Diego, CA, USA).
Transfection of small interfering RNA (siRNA)
To evaluate the efficiency of ABC transporters gene silencing, HEK293T cells (2.5 × 10 5 cells/well) were transfected with a range of 20 nM ABC transporters siRNA (Bioneer Inc., Daejeon, Korea) or 20 nM control siRNA using Lipofectamine ® RNAiMAX according to the manufacturer's protocol. The siRNA sequence of ABC transporters is shown in Table 1 . Total RNA from the HEK293T cells was extracted using NucleoSpin RNA Plus (Machery-Nagel Inc, Bethlehem, PA, USA) following manufacturer's protocol. Complementary DNA (cDNA) was synthesized by reverse transcription-PCR kit (iNtRON Biotechnology, Gyeonggi-do, Korea) with primers [44] . The primers for human ABC transporters used in this study are shown in Table 2 . The mRNA levels of ABC transporters were determined by qRT-PCR using SYBR Green PCR Master Mix (Promega, Madison, WI, USA) according to the protocols provided by the manufacturer with an ABI prism 7700 Sequence Detector System (Applied Biosystems, CA, USA). Target gene mRNA expression levels were calculated using the ∆Ct method and normalized to glyceraldehyde 3-phosphate dehydrogenase mRNA expression. 
Fractionation of Plasma Membrane
The plasma membrane of HEK293T cells, which had been transfected with ABCA1 siRNA, was prepared by sucrose density gradient centrifugation as described previously [15] . The membrane pellet was analyzed by immunoblotting using anti-ABCA1 and anti-N-cadherin antibodies.
Immunoprecipitation
To analyze the Ac-APE1/Ref-1 in cell lysate, immunoprecipitation using anti-acetyl lysine antibody was performed as previously reported [15] with some modifications. Co-immunoprecipitation using monoclonal anti-ABCA1 antibody and polyclonal anti-APE1/Ref-1 was also performed to analyze the binding between ABCA1 and APE1/Ref-1 in cell lysate. Briefly, the one microgram of each antibodies was added to cell lysate and incubated for 2 h at 4 • C. Protein A/G agarose beads were then added to each sample and incubated for 18 h at 4 • C. The immunocomplex was collected using centrifugation at 300 rpm for 3 min and washed three times in washing buffer. Each sample was subjected to 10~12% SDS-PAGE, which was followed by immunoblotting using monoclonal anti-APE1/Ref-1 antibody and polyclonal anti-ABCA1 antibody.
Proximal Ligation Assay
Interaction of ABCA1 and APE1/Ref-1 was visualized using a Duolink II fluorescence kit (Sigma-Aldrich, St Louis, MO, USA) as described previously [15] , with some modifications. HEK293T cells expressing wild type APE1/Ref-1-FLAG [45] or mutant APE1/Ref-1(K6/7R)-FLAG [46] grown on glass coverslips were treated with TSA for 1h. After fixation and blocking the cells were incubated with a mixture of goat anti-ABCA1 antibody (1:200) and rabbit anti-APE1/Ref-1 antibody (1:500) overnight at 4 • C. For in situ analysis, conjugated oligonucleotides [PLA probe anti-goat minus (minus strand) plus anti-rabbit antibody (plus strand)] were added and incubated for 1 h at 37 • C. A negative control was prepared by adding anti-mouse IgG. Fluorescence confocal microscopic images of the cells were acquired using excitation/emission wavelengths of 590/670 nm for the PLA signal and 410/470 nm for the DAPI (Sigma-Aldrich, St Louis, MO, USA). Images were acquired with a confocal TCS SP8 X microscope (Leica, Wetzlar, Germany) with 40× oil immersion objective. Z-stack image were collected at 0.4 µm intervals. The obtained images were processed using Leica LAS X software (Leica, Wetzlar, Germany).
Statistical analysis
Values are expressed as means ± standard error of means (SEM). Statistical significance of differences in measured variables between control and treated groups was determined by paired t-test, one-way ANOVA or two-way ANOVA followed by Bonferroni's multiple comparison tests. The differences were considered to be significant at p < 0.05. 
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